GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
ConditionBiliary Tract Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFudan University
About this trial
In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Donafenib and Tislelizumab for patients with advanced biliary tract carcinoma.
Eligibility criteria
Qualifiers
Age ≥18 years and ≤75 years;
ECOG physical condition score: 0~1;
Histologically or cytologically confirmed advanced biliary tract carcinoma (including gallbladder, intrahepatic and extrahepatic cholangiocarcinoma);
Preoperative imaging assessment of the disease stage was III/IV;
Disqualifiers
Patients with other uncured malignant tumors;
Pregnant or lactating women who are required to withdraw from the clinical trial if they become pregnant during the study period;
Previous antitumor therapy for the disease in this study;
Participated in clinical trials of other drugs within one month;
Trial design
Treatments tested in this trial
- Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Treatment groups
93 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov